Javier Rodriguez - Mar 14, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Legal Officer, Senior Vice President and Corporate Secretary
Signature
/s/ Javier Rodriguez
Stock symbol
BTAI
Transactions as of
Mar 14, 2023
Transactions value $
-$18,644
Form type
4
Date filed
3/16/2023, 05:58 PM
Previous filing
May 17, 2022
Next filing
May 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +2.08K 2.08K Mar 14, 2023 Direct F1
transaction BTAI Common Stock Sale -$18.6K -950 -45.56% $19.63 1.14K Mar 15, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -2.08K -25% $0.00 6.25K Mar 14, 2023 Common Stock 2.08K Direct F1, F3
transaction BTAI Restricted Stock Units Award $0 +9K $0.00 9K Mar 15, 2023 Common Stock 9K Direct F1, F4
transaction BTAI Stock Option (Right to Buy) Award $0 +32K $0.00 32K Mar 15, 2023 Common Stock 32K $19.60 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2022.
F3 On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4 The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F5 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Remarks:

Chief Legal Officer, Senior Vice President and Corporate Secretary